Increased extracellular amyloid deposition and neurodegeneration in human amyloid precursor protein transgenic mice deficient in receptor-associated protein

被引:0
作者
Van Uden, E
Mallory, M
Veinbergs, I
Alford, M
Rockenstein, E
Masliah, E [1 ]
机构
[1] Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA
关键词
amyloid beta protein; amyloid precursor protein; apopoliprotein E; low-density lipoprotein receptor; receptor-associated protein; transgenic mice;
D O I
暂无
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The low-density lipoprotein receptor-related protein (LRP) is an abundant neuronal cell surface receptor that regulates amyloid beta-protein (Abeta) trafficking into the cell. Specifically, LRP binds secreted Abeta complexes and mediates its degradation. Previously, we have shown in vitro that the uptake of Abeta mediated by LRP is protective and that blocking this receptor significantly enhances neurotoxicity. To further characterize the effects of LRP and other lipoprotein receptors on Abeta deposition, an in vivo model of decreased LRP expression, receptor-associated protein (RAP)-deficient (RAP-/-) mice was crossed with human amyloid protein precursor transgenic (hAPP tg) mice, and plaque formation and neurodegeneration were analyzed. We found that, although the age of onset for plaque formation was the same in hAPP tg and hAPP tg/RAP-/- mice, the amount of amyloid deposited doubled in the hAPP tg/RAP-/- background. Moreover, these mice displayed increased neuronal damage and astrogliosis. Together, these results further support the contention that LRP and other lipoprotein receptors might be neuroprotective against Abeta toxicity and that this receptor might play an integral role in Abeta clearance.
引用
收藏
页码:9298 / 9304
页数:7
相关论文
共 59 条
[11]   Microglia, scavenger receptors, and the pathogenesis of Alzheimer's disease [J].
El Khoury, J ;
Hickman, SE ;
Thomas, CA ;
Loike, JD ;
Silverstein, SC .
NEUROBIOLOGY OF AGING, 1998, 19 (01) :S81-S84
[12]   Activated α2macroglobulin increases β-amyloid (25-35)-induced toxicity in LAN5 human neuroblastoma cells [J].
Fabrizi, C ;
Businaro, R ;
Lauro, GM ;
Starace, G ;
Fumagalli, L .
EXPERIMENTAL NEUROLOGY, 1999, 155 (02) :252-259
[13]   ALZHEIMER-TYPE NEUROPATHOLOGY IN TRANSGENIC MICE OVEREXPRESSING V717F BETA-AMYLOID PRECURSOR PROTEIN [J].
GAMES, D ;
ADAMS, D ;
ALESSANDRINI, R ;
BARBOUR, R ;
BERTHELETTE, P ;
BLACKWELL, C ;
CARR, T ;
CLEMENS, J ;
DONALDSON, T ;
GILLESPIE, F ;
GUIDO, T ;
HAGOPIAN, S ;
JOHNSONWOOD, K ;
KHAN, K ;
LEE, M ;
LEIBOWITZ, P ;
LIEBERBURG, I ;
LITTLE, S ;
MASLIAH, E ;
MCCONLOGUE, L ;
MONTOYAZAVALA, M ;
MUCKE, L ;
PAGANINI, L ;
PENNIMAN, E ;
POWER, M ;
SCHENK, D ;
SEUBERT, P ;
SNYDER, B ;
SORIANO, F ;
TAN, H ;
VITALE, J ;
WADSWORTH, S ;
WOLOZIN, B ;
ZHAO, J .
NATURE, 1995, 373 (6514) :523-527
[14]   SEGREGATION OF A MISSENSE MUTATION IN THE AMYLOID PRECURSOR PROTEIN GENE WITH FAMILIAL ALZHEIMERS-DISEASE [J].
GOATE, A ;
CHARTIERHARLIN, MC ;
MULLAN, M ;
BROWN, J ;
CRAWFORD, F ;
FIDANI, L ;
GIUFFRA, L ;
HAYNES, A ;
IRVING, N ;
JAMES, L ;
MANT, R ;
NEWTON, P ;
ROOKE, K ;
ROQUES, P ;
TALBOT, C ;
PERICAKVANCE, M ;
ROSES, A ;
WILLIAMSON, R ;
ROSSOR, M ;
OWEN, M ;
HARDY, J .
NATURE, 1991, 349 (6311) :704-706
[15]   VLDL receptor polymorphism, cognitive impairment, and dementia [J].
Helbecque, N ;
Berr, C ;
Cottel, D ;
Fromentin-David, I ;
Sazdovitch, V ;
Ricolfi, F ;
Ducimetière, P ;
Di Menza, C ;
Amouyel, P .
NEUROLOGY, 2001, 56 (09) :1183-1188
[16]   Apolipoprotein E receptors: Linking brain development and Alzheimer's disease [J].
Herz, J ;
Beffert, U .
NATURE REVIEWS NEUROSCIENCE, 2000, 1 (01) :51-58
[17]   Lipoprotein receptors: beacons to neurons? [J].
Herz, J .
TRENDS IN NEUROSCIENCES, 2001, 24 (04) :193-195
[18]   The LDL receptor gene family: (Un)expected signal transducers in the brain [J].
Herz, J .
NEURON, 2001, 29 (03) :571-581
[19]  
HERZ J, 1991, J BIOL CHEM, V266, P21232
[20]   LRP: a multifunctional scavenger and signaling receptor [J].
Herz, J ;
Strickland, DK .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 108 (06) :779-784